Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Abstract 5794: Tumor cell targeted granzyme B fusion constructs mediate immunogenic cell death (ICD) in addition to their direct cytotoxic effects

Khalid A. Mohamedali, Brian Aguirre, Lawrence H. Cheung, SuYin Kok, David Casero, Madhuri Wadehra, Michael G. Rosenblum

Cancer Res (2025) 85 (8_Supplement_1): 5794.

https://doi.org/10.1158/1538-7445.AM2025-5794

Published: 21 April 2025

View articletitled, Abstract 5794: Tumor cell targeted granzyme B fusion constructs mediate immunogenic cell death (ICD) in addition to their direct cytotoxic effects

Journal Articles

Abstract 2606: Targeting mesothelin on tumor cells with a novel, completely human fusion construct delivering the serine protease granzyme B

Khalid A. Mohamedali, Lawrence H. Cheung, Mihai G. Iurascu, Louis R. DePalatis, Claire Thuning-Roberson, Michael G. Rosenblum

Cancer Res (2024) 84 (6_Supplement): 2606.

https://doi.org/10.1158/1538-7445.AM2024-2606

Published: 22 March 2024

View articletitled, Abstract 2606: Targeting mesothelin on tumor cells with a novel, completely human fusion construct delivering the serine protease granzyme B

Journal Articles

Abstract 2603: Targeting chemo-resistant ovarian cancer with a first-in-class, first-in-human immune-oncology agents containing granzyme B

Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Michael G. Rosenblum

Cancer Res (2024) 84 (6_Supplement): 2603.

https://doi.org/10.1158/1538-7445.AM2024-2603

Published: 22 March 2024

View articletitled, Abstract 2603: Targeting chemo-resistant ovarian cancer with a first-in-class, first-in-human immune-oncology agents containing granzyme B

Journal Articles

Abstract 5974: Targeting VEGFR on tumor cells and activated vasculature through delivery of granzyme B

Khalid A. Mohamedali, Lawrence H. Cheung, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2024) 84 (6_Supplement): 5974.

https://doi.org/10.1158/1538-7445.AM2024-5974

Published: 22 March 2024

View articletitled, Abstract 5974: Targeting VEGFR on tumor cells and activated vasculature through delivery of granzyme B

Journal Articles

Abstract 3901: Identification of genomic pathways associated with resistance of NSCLC to immunotherapies containing granzyme B

Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Ganiraju C. Manyam, Jing Wang, John V. Heymach, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 3901.

https://doi.org/10.1158/1538-7445.AM2023-3901

Published: 04 April 2023

View articletitled, Abstract 3901: Identification of genomic pathways associated with resistance of NSCLC to immunotherapies containing granzyme B

Journal Articles

Abstract 6316: In vitro and in vivo studies of human granzyme B fusion constructs targeting mesothelin

Khalid A. Mohamedali, Lawrence H. Cheung, Louis R. DePalatis, Claire Thuning-Roberson, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6316.

https://doi.org/10.1158/1538-7445.AM2023-6316

Published: 04 April 2023

View articletitled, Abstract 6316: In vitro and in vivo studies of human granzyme B fusion constructs targeting mesothelin

Journal Articles

Abstract 6315: Human granzyme B fusions targeting VEGFR on tumor cells and activated vasculature

Khalid A. Mohamedali, Lawrence H. Cheung, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6315.

https://doi.org/10.1158/1538-7445.AM2023-6315

Published: 04 April 2023

View articletitled, Abstract 6315: Human granzyme B fusions targeting VEGFR on tumor cells and activated vasculature

Journal Articles

Abstract 6314: Novel granzyme B-based fusion constructs targeting FRα on liquid and solid tumors

Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Natalia Baran, Marina Konopleva, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6314.

https://doi.org/10.1158/1538-7445.AM2023-6314

Published: 04 April 2023

View articletitled, Abstract 6314: Novel granzyme B-based fusion constructs targeting FRα on liquid and solid tumors

Journal Articles

Abstract 6313: IND-enabling studies for GrB-Fc-IT4: in vivo efficacy, pharmacokinetics, schedule optimization and maximum tolerated dose

Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Mihai Gagea, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6313.

https://doi.org/10.1158/1538-7445.AM2023-6313

Published: 04 April 2023

View articletitled, Abstract 6313: IND-enabling studies for GrB-Fc-IT4: in vivo efficacy, pharmacokinetics, schedule optimization and maximum tolerated dose

Journal Articles

Abstract 6317: Targeting cell-surface CEA with a novel human fusion construct delivers the serine protease granzyme B to solid tumor cells

Khalid A. Mohamedali, Ana Alvarez-Cienfuegos, Lawrence H. Cheung, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2023) 83 (7_Supplement): 6317.

https://doi.org/10.1158/1538-7445.AM2023-6317

Published: 04 April 2023

View articletitled, Abstract 6317: Targeting cell-surface CEA with a novel human fusion construct delivers the serine protease granzyme B to solid tumor cells

Journal Articles

Abstract 337: Development of an immune-oncology agent containing granzyme B to target VEGFR+ ovarian cancer cells and activated tumor vasculature

Khalid A. Mohamedali, Lawrence H. Cheung, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2022) 82 (12_Supplement): 337.

https://doi.org/10.1158/1538-7445.AM2022-337

Published: 15 June 2022

View articletitled, Abstract 337: Development of an immune-oncology agent containing granzyme B to target VEGFR+ ovarian cancer cells and activated tumor vasculature

Journal Articles

Abstract 5216: Optimizing antitumor efficacy of granzyme B human fusion constructs targeting the Fn14 antigen in solid tumors. Pre IND pharmacokinetics, schedule, dose optimization and MTD studies

Ana Alvarez De Cienfuegos, Lawrence H. Cheung, Khalid A. Mohamedali, Mihai Gagea, Michael G. Rosenblum

Cancer Res (2022) 82 (12_Supplement): 5216.

https://doi.org/10.1158/1538-7445.AM2022-5216

Published: 15 June 2022

View articletitled, Abstract 5216: Optimizing antitumor efficacy of granzyme B human fusion constructs targeting the Fn14 antigen in solid tumors. Pre IND pharmacokinetics, schedule, dose optimization and MTD studies

Journal Articles

Abstract 3439: An internalizing anti-CEA construct for targeted delivery of granzyme B results in significant antitumor activity in human lung carcinoma xenografts

Lawrence H. Cheung, Khalid A. Mohamedali, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2022) 82 (12_Supplement): 3439.

https://doi.org/10.1158/1538-7445.AM2022-3439

Published: 15 June 2022

View articletitled, Abstract 3439: An internalizing anti-CEA construct for targeted delivery of granzyme B results in significant antitumor activity in human lung carcinoma xenografts

Journal Articles

Abstract 5194: Development of a cytotoxic fusion protein targeting VEGF receptors with improved cytotoxicity, stability and pharmacokinetics

Khalid A. Mohamedali, Lawrence H. Cheung, Ana A. Alvarez-Cienfuegos, Michael G. Rosenblum

Cancer Res (2020) 80 (16_Supplement): 5194.

https://doi.org/10.1158/1538-7445.AM2020-5194

Published: 15 August 2020

View articletitled, Abstract 5194: Development of a cytotoxic fusion protein targeting VEGF receptors with improved cytotoxicity, stability and pharmacokinetics

Journal Articles

Abstract 2891: Targeting breast cancer stem cells with anti-EMP2 immunotoxins delivering granzyme b

Khalid A. Mohamedali, Kok Su-yin, Lawrence H. Cheung, Naina Dhawan, Michael G. Rosenblum, Madhuri Wadehra

Cancer Res (2020) 80 (16_Supplement): 2891.

https://doi.org/10.1158/1538-7445.AM2020-2891

Published: 15 August 2020

View articletitled, Abstract 2891: Targeting breast cancer stem cells with anti-EMP2 immunotoxins delivering granzyme b

Journal Articles

Abstract 1218: EMP2 serves as a novel target for immunotoxin mediated ovarian cancer therapy

Khalid Mohamedali, Su-Yin Kok, Lawrence H. Cheung, Michael G. Rosenblum, Madhuri Wadehra

Cancer Res (2019) 79 (13_Supplement): 1218.

https://doi.org/10.1158/1538-7445.AM2019-1218

Published: 01 July 2019

View articletitled, Abstract 1218: EMP2 serves as a novel target for immunotoxin mediated ovarian cancer therapy

Journal Articles

Abstract 2396: Development of a new generation of dimeric, highly cytotoxic fusion proteins containing active GrB and VEGF targeting tumor neovasculature: Incorporating IgG heavy chain Fc fragments improves cytotoxicity, stability and pharmacokinetics

Khalid A. Mohamedali, Lawrence H. Cheung, Ana Alvarez-Cienfuegos, Michael G. Rosenblum

Cancer Res (2019) 79 (13_Supplement): 2396.

https://doi.org/10.1158/1538-7445.AM2019-2396

Published: 01 July 2019

View articletitled, Abstract 2396: Development of a new generation of dimeric, highly cytotoxic fusion proteins containing active GrB and VEGF targeting tumor neovasculature: Incorporating IgG heavy chain Fc fragments improves cytotoxicity, stability and pharmacokinetics

Journal Articles

Abstract 2780: Engineering human fusion constructs for targeted delivery of granzyme B to CD33 and CEA antigens

Lawrence H. Cheung, Khalid A. Mohamedali, Walter N. Hittelman, Michael G. Rosenblum

Cancer Res (2018) 78 (13_Supplement): 2780.

https://doi.org/10.1158/1538-7445.AM2018-2780

Published: 01 July 2018

View articletitled, Abstract 2780: Engineering human fusion constructs for targeted delivery of granzyme B to CD33 and CEA antigens

Journal Articles

Abstract 4182: Impacting early events in metastatic spread: Targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases

Khalid A. Mohamedali, Lawrence H. Cheung, Michael G. Rosenblum

Cancer Res (2018) 78 (13_Supplement): 4182.

https://doi.org/10.1158/1538-7445.AM2018-4182

Published: 01 July 2018

View articletitled, Abstract 4182: Impacting early events in metastatic spread: Targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases

Journal Articles

Abstract 4587: A human hybrid immuno-oncology construct targeting the TWEAK receptor Fn14 and containing the serine protease granzyme B

Ana Alvarez de Cienfuegos, Lawrence H. Cheung, Khalid A. A. Mohamedali, Jeffrey A. Winkles, Michael G. Rosenblum

Cancer Res (2017) 77 (13_Supplement): 4587.

https://doi.org/10.1158/1538-7445.AM2017-4587

Published: 01 July 2017

View articletitled, Abstract 4587: A human hybrid immuno-oncology construct targeting the TWEAK receptor Fn14 and containing the serine protease granzyme B

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 5794: Tumor cell targeted granzyme B fusion constructs mediate immunogenic cell death (ICD) in addition to their direct cytotoxic effects

Abstract 2606: Targeting mesothelin on tumor cells with a novel, completely human fusion construct delivering the serine protease granzyme B

Abstract 2603: Targeting chemo-resistant ovarian cancer with a first-in-class, first-in-human immune-oncology agents containing granzyme B

Abstract 5974: Targeting VEGFR on tumor cells and activated vasculature through delivery of granzyme B

Abstract 3901: Identification of genomic pathways associated with resistance of NSCLC to immunotherapies containing granzyme B

Abstract 6316: In vitro and in vivo studies of human granzyme B fusion constructs targeting mesothelin

Abstract 6315: Human granzyme B fusions targeting VEGFR on tumor cells and activated vasculature

Abstract 6314: Novel granzyme B-based fusion constructs targeting FRα on liquid and solid tumors

Abstract 6313: IND-enabling studies for GrB-Fc-IT4: in vivo efficacy, pharmacokinetics, schedule optimization and maximum tolerated dose

Abstract 6317: Targeting cell-surface CEA with a novel human fusion construct delivers the serine protease granzyme B to solid tumor cells

Abstract 337: Development of an immune-oncology agent containing granzyme B to target VEGFR+ ovarian cancer cells and activated tumor vasculature

Abstract 5216: Optimizing antitumor efficacy of granzyme B human fusion constructs targeting the Fn14 antigen in solid tumors. Pre IND pharmacokinetics, schedule, dose optimization and MTD studies

Abstract 3439: An internalizing anti-CEA construct for targeted delivery of granzyme B results in significant antitumor activity in human lung carcinoma xenografts

Abstract 5194: Development of a cytotoxic fusion protein targeting VEGF receptors with improved cytotoxicity, stability and pharmacokinetics

Abstract 2891: Targeting breast cancer stem cells with anti-EMP2 immunotoxins delivering granzyme b

Abstract 1218: EMP2 serves as a novel target for immunotoxin mediated ovarian cancer therapy

Abstract 2396: Development of a new generation of dimeric, highly cytotoxic fusion proteins containing active GrB and VEGF targeting tumor neovasculature: Incorporating IgG heavy chain Fc fragments improves cytotoxicity, stability and pharmacokinetics

Abstract 2780: Engineering human fusion constructs for targeted delivery of granzyme B to CD33 and CEA antigens

Abstract 4182: Impacting early events in metastatic spread: Targeted therapeutics to disrupt formation of the pre-metastatic niche and development of lung metastases

Abstract 4587: A human hybrid immuno-oncology construct targeting the TWEAK receptor Fn14 and containing the serine protease granzyme B

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only